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Genomic Profiling of a Human Organotypic Model
of AEC Syndrome Reveals ZNF750 as an Essential
Downstream Target of Mutant TP63
Brian J. Zarnegar,1 Dan E. Webster,1 Vanessa Lopez-Pajares,1 Brook Vander Stoep Hunt,1 Kun Qu,1
Karen J. Yan,1 David R. Berk,2 George L. Sen,3 and Paul A. Khavari1,4,*
The basis for impaired differentiation in TP63 mutant ankyloblepharon-ectodermal dysplasia-clefting (AEC) syndrome is unknown.
Human epidermis harboring AEC TP63mutants recapitulated this impairment, along with downregulation of differentiation activators,
including HOPX, GRHL3, KLF4, PRDM1, and ZNF750. Gene-set enrichment analysis indicated that disrupted expression of epidermal
differentiation programs under the control of ZNF750 and KLF4 accounted for themajority of disrupted epidermal differentiation result-
ing from AEC mutant TP63. Chromatin immunoprecipitation (ChIP) analysis and ChIP-sequencing of TP63 binding in differentiated
keratinocytes revealed ZNF750 as a direct target of wild-type and AECmutant TP63. Restoring ZNF750 to AECmodel tissue rescued acti-
vator expression and differentiation, indicating that AEC TP63-mediated ZNF750 inhibition contributes to differentiation defects in
AEC. Incorporating disease-causing mutants into regenerated human tissue can thus dissect pathomechanisms and identify targets
that reverse disease features.Introduction
TP63 (MIM 603273) is essential for the development and
homeostasis of stratified epithelia.1–5 TP63 exists in
multiple isoforms; however, in developmentally mature
epidermis, the predominant isoform is DNp63a.6 Consis-
tent with this, genetic ablation of TA isoforms does not
markedly impact epidermal homeostasis or differentia-
tion.7 Importantly, previous studies have demonstrated
that TP63 is required for both the maintenance of
epidermal progenitor proliferation as well as differentia-
tion.4,8 How TP63 executes both functions remains incom-
pletely understood.
Heterozygous, dominant mutations in TP63 cause a
number of monogenic human diseases that share the
common feature of abnormal epithelia, including ecto-
dermal dysplasia. Among these disorders are ankyloble-
pharon-ectodermal dysplasia-clefting syndrome (AEC
[MIM 106260])9, ectrodactyly-ectodermal dysplasia-cleft-
ing syndrome (EEC [MIM 604292]),10 limb-mammary
syndrome (LMS [MIM 603543]),10 acro-dermato-ungual-
lacrimal-tooth syndrome (ADULT [MIM 103285]),11 Rapp-
Hodgkin syndrome (RHS [MIM 129400]),12,13 and split
hand/foot malformation (SHFM [MIM605289]).14 Intrigu-
ingly, despite the fact that all these disorders result from
heterozygous TP63 mutations, impaired epidermal differ-
entiation with epidermal erosions is characteristic in indi-
viduals with AEC but is rarely seen in other syndromes,15
whereas severe limb abnormalities common to EEC are
not seen in individuals with AEC.16 These findings suggest
that the mutations causing each syndrome impair specific
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The AmericanTP63 syndromes arise from mutations that affect
discrete domains of TP63. AEC itself is characterized by
mutations in the C-terminal portion of the sterile alpha
motif (SAM) domain, which is specific to TP63a iso-
forms.17 EEC mutations, in contrast, predominantly
localize in the C-terminal portion of the TP63 DNA
binding domain. Previous work has shown that TP63-
EEC mutants are defective in the induction of DLX5 and
DLX6, which are implicated in the pathogenesis of EEC
phenotypes (MIMs 600028 and 600030).18–20 Remarkably,
AEC mutants are capable of DLX5 and DLX6 transactiva-
tion, demonstrating that AEC mutants retain important
TP63 functions.20 The mechanism by which AEC muta-
tion impairs epidermal differentiation is unknown.
Here, we introduce AEC TP63 mutants in regenerated
human epidermal tissue, both to model epidermal features
of AEC and to gain insight into the mechanisms whereby
these mutants disrupt epidermal differentiation. Multiple
independent AEC TP63 mutants confirmed that intro-
ducing thesemutants into postnatal regenerated epidermis
is sufficient to disrupt epidermal differentiation. Profiling
AEC model tissue showed repression of established
transcriptional activators of epidermal differentiation,
including HOPX (MIM 607275), GRHL3 (MIM 608317),
KLF4 (MIM 602253), and PRDM1 (MIM 6034230). Also
repressed was ZNF750 (MIM 610226), a recently character-
ized effector of epidermal differentiation that is also associ-
ated with impaired epidermal differentiation in a single
extended family (MIM 610227).21,22 ZNF750 was found
to be both TP63-dependent and bound by TP63 via
chromatin immunoprecipitation sequencing (ChIP-Seq)
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of AEC mutants in differentiating KCs showed that AEC
mutants, like wild-type TP63, retained the ability to bind
the ZNF750 promoter in spite of their repression of
ZNF750 induction. Remarkably, enforcing ZNF750 expres-
sion in AEC model tissue significantly rescued HOPX,
GRHL3, KLF4, and PRDM1 differentiation-activator expres-
sion and impaired epidermal differentiation. These find-
ings indicate that ZNF750 repression by AEC TP63
mutants contributes to the impaired epidermal differentia-
tion seen in AEC and suggest that introducing mutant
genes responsible for monogenic disorders within regener-
ated human tissue may represent a useful approach to
understanding disease pathogenesis.Material and Methods
Human Subjects
Specific consent was obtained for use of the AEC tissue biopsy. All
experiments adhered to institutional review board-approved
protocols of Stanford University and the Barnes-Jewish Hospital
of St. Louis, Washington University School of Medicine.
Cell Culture and Organotypic Culture of Human Skin
Primary human neonatal KCs were isolated from freshly discarded
foreskin specimens. KCs were grown in KC serum-free medium
(KSFM) (Gibco BRL) supplemented with epidermal growth factor
and bovine pituitary extract. KC differentiation was induced via
the addition of 1.2 mM calcium for 3 days at full confluence. For
organotypic skin cultures, 5 3 105 cells were seeded onto devital-
ized human dermis and raised to the air/liquid interface for
inducing KC stratification and differentiation, as described previ-
ously.23,24 Organotypic tissue experiments spanned a duration of
4 days. Puromycin drug selection (1 mg/ml) was maintained for
sustaining delivered vectors throughout this time course; sus-
tained stable wild-type TP63 and AEC TP63 mutant expression
was confirmed throughout the organotypic tissue time course
for all experiments via immunoblotting and quantitative PCR
(qPCR).
Retroviral Constructs
cDNA of wild-type murine TP63-DNa and human ZNF750 was
subcloned into the pBABE-puro retroviral vector via the BamHI
and SalI sites. We used the murine cDNA sequence of TP63-DNa
(RefSeq accession number AF075439.1) to prevent human-specific
small interfering RNA (siRNA) (see Figure S1 available online) from
targeting exogenously expressed TP63. The amino acid sequence
of murine TP63-DNa was humanized via sequential QuikChange
(Stratagene)-mediated mutagenesis. Substituted nucleotides were
c.G820>A, c.A1085>C, c.C1558_1559delinsAG, c.G1582>A,
and c.T1717>G, for generation of p.Ala274Thr, p.Gln362Pro,
p.Pro520Ser, p.Gly528Ser, and p.Ser537Ala, respectively. AEC
point mutants were then generated via QuikChange, with the
humanized pBABE-puro-TP63-DNa used as a template. Substituted
nucleotides were c.A1377>C, c.C1401>G, c.T1445>C, and
c.G1499>C, for generation of AEC mutants p.Leu459Phe,
p.Cys467Trp, p.Ile482Thr, and p.Arg500Pro, respectively. AEC
amino acid residues are numbered according to the TP63-DNa
sequence. Retrovirus was produced via Lipofectamine 2000 (Invi-
trogen)-mediated transfection of helper-free recombinant 293T-
based retroviral packaging cells. KCs were infected via 1 hr spin436 The American Journal of Human Genetics 91, 435–443, Septembat 32C in the presence of 5 mg/ml of polybrene. Immediately after
spin infection, cells were rinsed with PBS and returned to culture
in standard KSFM. Two days post infection, KC media was supple-
mented with 1 mg/ml puromycin, and cells were allowed to grow
for 1 week prior to experimental use.
RNAi
siRNA oligomers against the DNA binding domain (which targets
all isoforms) of TP63 were designed and synthesized by Dharma-
con: 50-CGACAGTCTTGTACAATTT. siRNA oligomers were mixed
with 53 106 primary human KCs, and the cells were then electro-
porated with a nucleofection kit (Amaxa, Gaithersburg, MD, USA)
according to the manufacturer’s protocol. Dharmacon-scrambled
siRNA oligomer, which is complementary to no known cellular
RNA, was used as a control. In knockdown experiments, KCs
were electroporated with the use of the T-007 high-viability
neonatal-KCs setting with 1,500 picomoles of the indicated olig-
omer. For protein analysis, electroporated cells were cultured in
KSFM for 3 days and then harvested for western blot analysis.
mRNA Expression Analysis
Total RNA from organotypic cultures or cultured cells was ex-
tracted with the RNeasy mini kit (QIAGEN) and quantified with
NanoDrop. One mg of total RNA was reverse transcribed with the
iScript RT-PCR kit from Bio-Rad. qPCR was performed with 2X
Maxima SYBR (Fermentas) on the Mx3000P (Stratagene) thermo-
cycler. Samples were run in triplicate and normalized to the ribo-
somal protein L32. See Supplemental Data for primer sequences
used for qPCR (Table S1).
Protein Levels
For immunoblotting, protein was harvested from cells in lysis
buffer, which consisted of 20 mM Tris (pH 7.5), 250 mM NaCL,
1mMEDTA, 1%NP40, and 0.2% SDS supplemented with protease
inhibitor (Complete Mini EDTA-free; Roche) and phosphatase
inhibitor mixture II (Sigma-Aldrich, St. Louis). For each sample,
30 mg of protein was boiled in SDS for 5 min and then run in
a 4%–12% SDS-PAGE gel. The protein was subsequently trans-
ferred to polyvinylidene fluoride membranes. Antibodies used
for immunoblotting included mouse anti-TP63 (4A4) (Santa
Cruz Biotechnology) and mouse anti-beta-actin (Sigma-Aldrich),
and sheep anti-mouse immunoglobulin G (IgG) conjugated to
horseradish peroxidase was purchased from Amersham Biosci-
ences (Piscataway, NJ, USA). For immunofluorescence experi-
ments, 7-mm-thick epidermal sections were fixed in ice-cold
methanol for 15 min, followed by blocking in PBS with 10% horse
serum for 30 min. Sections were incubated in primary antibodies
for 1 hr. Primary antibodies included keratin 1 (Covance: PRB-
149P, 1:2,000) and filaggrin (FLG) (PRB-417P, 1:1,000), with Alexa
555-conjugated goat anti-rabbit IgG (Molecular Probes, 1:1,000)
used as secondary. Nuclear dye, Hoechst 33342, was used at
1:1,000 (Molecular Probes).
ChIP and ChIP-Seq Assay
The formaldehyde crosslinking and immunoprecipitation (IP)
protocol was adapted from Wells and Farnham.25 Formaldehyde
(16% solution methanol-free; Pierce) was added to KCs resus-
pended in 10 ml PBS at a final concentration of 0.5%. Pellets
from approximately 1 3 106 cells were resuspended in 1 ml of
swelling buffer (50mM Tris [pH 7.6], 1% NP-40, 10 mM KAc,
15 mM MgAc, 1 mM phenylmethylsulfonyl fluoride [PMSF],er 7, 2012
1X Protease Inhibitor Cocktail [PIC] without EDTA [Roche]). After
20 min incubation on ice, cells were Dounce homogenized in a B
Dounce homogenizer. Nuclei were collected through centrifuga-
tion at 5,000 rpm, resuspended in 400 ml/1 3 106 cells of nuclei
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl [pH 8.0],
0.5 mM PMSF, and PIC), and incubated on ice for 30 min. Samples
were sonicated with a Bioruptor-200 (Diagenode) on the ‘‘high’’
setting for eight cycles of 30-s-on and 30-s-off pulses, for an
average length of 300 to 500 bp, and then microcentrifuged at
14,000 rpm. The chromatin solution was precleared with the addi-
tion of Staph A cells (prepared as described previously25 for 15min
at 4C). Precleared chromatin from 1.5 3 106 cells was incubated
with 2 mg of nonspecific rabbit IgG or anti-TP63 (Santa Cruz
4A4) at 4C for 12–18 hr with rotation. IP, washing, and elution
of immune complexes were carried out as described previously.
Prior to the first wash, 10% of the supernatant from the rabbit
IgG primary-antibody reaction for each sample was saved as total
input chromatin and was processed with the eluted immunopre-
cipitates, beginning at the crosslink-reversal step. After addition
of NaCl to 200 mM and 10 mg of RNase A, samples were incubated
at 65C overnight to reverse the crosslinks. Prior to DNA purifica-
tion with QIAGEN PCR-purification columns, 500 ml of Buffer PB
and 7.5 ml of 2M NaAc (pH 5.1) were added to the samples.
Columns were eluted twice with 50 ml of Buffer EB and 2 ml used
for all qPCRs. For ChIP-Seq experiments, the experimental condi-
tions were modified as follows: Chromatin was sonicated for
24 cycles of 30-s-on and 30-s-off pulses for an average length of
150 to 300 bp. Approximately 7.5 3 106 cells were used per IP.
Twenty mg of p63 (4A4) antibody was preconjugated onto Protein
G Dynabeads (Invitrogen) per IP. The libraries were prepared per
Illumina’s instructions. Libraries were sequenced on the Genome
Analyzer IIx (Illumina), with read lengths of 36 bp. Raw reads
were mapped to hg18 with Bowtie. ChIP signals were normalized
to 10 million mapped reads for each condition. Peaks of each
sample were called with MACS26 against input with a p value
cutoff of 1 3 109, false-discovery-rate cutoff of 0.05, tags cutoff
of 10, and fold-enrichment cutoff of 10. Normalized signal
within 2 kb upstream and downstream of the summits of pre-
dicted peaks was extracted with a smooth window size of 50 bp.
The control library was prepared identically, with the use of
~50 ng of input DNA.
Gene Expression Profiling
Amplification and labeling of cDNA probes and hybridization to
the Human Genome U133 Plus 2.0 microarray chip (Affymetrix)
were performed by the Stanford Protein and Nucleic Acid Facility.
Data analysis was performed with R. Each data set for an experi-
ment was filtered for probes that had an expression value R 100
in at least one of the samples along with a p value % 0.05, based
on SAM analysis. Pairwise comparisons between the RNAi-treated
samples and the control samples were performed for discovery of
probes that showed R 1.8-fold expression change. Hierarchical
clustering and heat-map generation were performed with Cluster
and TreeView. p values indicating the significance of the
overlap between various gene sets were calculated with Fisher’s
exact test. Gene ontology term enrichment was performed with
DAVID with the total set of genes on the appropriate microarray
as the background. p values represent a Bonferroni-corrected
modified Fisher’s exact test. Gene sets for epidermal regulators
significantly associated with the AEC and TP63i signature were
acquired from the Gene Expression Omnibus (GEO) or the Euro-
pean Bioinformatics Institute (accession numbers: ZNF750 andThe AmericanKLF4, GSE32685; IRF6, GSE5800; GRHL3, GSE7381; CEBPa and
CEBPb, E-MEXP-1719; EFNA, GSE26521; Notch1, GSE23782) or
from a supplemental table for ETS1. Gene expression data was
processed in R with the use of SAM with a p value % 0.05 cutoff
for differentially expressed genes with R 2-fold expression
change. Gene-set enrichment analysis (GSEA) was conducted
with Genomica software, with p value % 0.05 for significant
enrichment.Results
The impaired epidermal differentiation observed in AEC
syndrome might result both from the persistence of
a deficit programmed during development and from
TP63-mutant-mediated disruption of differentiation in
developmentally mature tissue. For examination of the
latter role of AEC mutant TP63, cDNA encoding TP63-
DNa-WT or AEC mutants found in humans, including
TP63-DNa-p.Cys467Trp, TP63-DNa-p.Leu459Phe, TP63-
DNa-p.Ile482Thr, and TP63-DNa-p.Arg500Pro, was intro-
duced within regenerated organotypic human epidermis.
Importantly, for accurate modeling of the heterozygous
TP63 state of AEC human tissue, rigorous controls were
used for verifying stable physiological levels of TP63
mutants in the context of normal endogenous TP63 for
all studies (see Material and Methods; Figures S1A–S1C).
Resulting cells were then used to regenerate epidermal
tissue on intact human dermis in organotypic culture via
an approach demonstrated to recapitulate much of the
morphology and gene expression of normal human
skin.21,23,24,27 In contrast to controls, each of the AEC
TP63 mutants profoundly impaired the levels of canonical
epidermal differentiation markers, including KRT1 (MIM
139350) and FLG (MIM 135940) (Figures 1A and B), as
well as SPRR1A (MIM 182265), SPRR3 (MIM 182271),
TGM1 (MIM 606776), DSC1 (MIM 125643), LOR (MIM
152445), LCE3D (MIM 612616), and LCE1E (MIM
612607) (Figures S2A and S2B). TUNEL staining indicated
that this disrupted differentiation-gene expression was
not accompanied by apoptosis. Diminished levels of differ-
entiation proteins, such as KRT1 and FLG, in AEC organo-
typic tissue agree with a previous study of AEC skin,28
which we also independently reverified using AEC skin
biopsy specimens (Figures 1C and 1D). Whereas control
tissue demonstrated proliferation that was appropriately
localized to the basal layer, as previously noted in organo-
typic epidermis, wherein proliferation and differentiation
faithfully recapitulate their normal spatial localization by
1 week time points of full regeneration,23 AEC tissue
exhibited abnormal suprabasal Ki67 staining, consistent
with observations seen in AEC skin28 (Figure S3). Clono-
genic assays did not reveal defective proliferation of AEC
mutant KCs, as recently observed in a knockin mouse
model of AEC syndrome,29 indicating that this phenotype
may arise from a developmental defect caused by mutant
TP63 (Figure S4). The disrupted epidermal differentiation
seen in regenerated human tissue upon introduction ofJournal of Human Genetics 91, 435–443, September 7, 2012 437
Figure 1. Disrupted Epidermal Differen-
tiation by AEC TP63 Mutants in Regener-
ated Organotypic Human Epidermal
Tissue
Differentiation markers (A) KRT1 and (B)
FLG in control (EV), TP63-DNp63a-WT
(WT), TP63-DNp63a-Cys467Trp, TP63-
DNp63a-Leu459Phe, TP63-DNp63a-I-
le482Thr, and TP63-DNp63a-Arg500Pro
AEC mutant-expressing regenerated orga-
notypic human epidermal tissue (orange ¼
differentiation protein, blue ¼ Hoechst
33342 nuclei, dotted line denotes basement
membrane). Differentiation markers (C)
KRT1 and (D) FLG in normal skin and in
AEC lesional skin from a 1-day-old AEC-
affected individual with a confirmed
p.Phe458Ser alteration.
Figure 2. Retention of Mutated SAM Domain in TP63 AEC
Mutants Is Required for Inhibition of Epidermal Differentiation
(A) Immunoblot analysis of TP63-DNp63a levels in human KCs
transduced with TP63-DNp63a-WT, TP63-DNp63a-Arg500Pro,
and TP63-DNp63d. KCs were treated with control or TP63 target-
ing siRNA, as indicated.
(B) KRT1 in TP63-DNp63a-WT, TP63-DNp63a-Arg500Pro, and
TP63-DNp63d expressing regenerated organotypic human
epidermal tissue (orange¼ differentiation protein, blue¼Hoechst
33342, green ¼ basement membrane).AEC mutants suggests that these mutants can also impair
this process in developmentally mature postnatal cells
and also generate a human epidermal tissue model in
which to study the differentiation defects observed in AEC.
The dominant effects on epidermal differentiation of
AEC-associated mutations in the TP63 SAM domain raised
the question as to whether these effects are due to lost
function of the entire TP63aC-terminal region, or whether
they require retention of mutated C-terminal TP63 resi-
dues. For testing of this, cDNA encoding TP63-DNa-WT,
TP63-DNa-p.Arg500Pro, or TP63-DNd, which lacks the
entire C-terminal SAM domain mutated in AEC and is
normally not present at significant levels in epidermis,30
was introduced within regenerated organotypic human
epidermis. Physiologic levels of TP63 constructs were
confirmed by specific silencing of endogenous TP63
(Figure 2A). In contrast to AEC p.Arg500Pro mutant tissue,
regenerated epidermal tissue harboring TP63-DNd in the
context of normal endogenous TP63 engaged differentia-
tion-protein production normally (Figure 2B), suggesting
that retention of mutated TP63 SAM-domain-containing
C-terminal residues are important for the differentiation-
suppressive effects of AEC mutant TP63.
To characterize the impaired epidermal differentiation
observed in AEC model tissue further, we performed tran-
scriptional profiling on AEC mutant regenerated human
organotypic epidermis. This revealed 1,185 (533 repressed;
652 induced) and 864 (499 repressed; 365 induced) differ-
entially expressed genes in the AEC-p.Ile482Thr and AEC-
p.Arg500Pro mutant organotypic tissues, respectively
(Tables S2 and S3). Comparison of these gene sets showed
a significant (p < 10250) overlap of 651 genes between438 The American Journal of Human Genetics 91, 435–443, September 7, 2012these mutants (Figure 3A and Table
S4). Repressed genes in the shared
gene set were significantly enriched
for gene ontology terms associated
with epidermal development and
differentiation, whereas the induced
genes showed no significant enrich-
ment for any gene ontology terms(Figure 3B). AEC TP63 mutants thus broadly block induc-
tion of genes involved in epidermal differentiation.
TP63 is required for normal epidermal differentia-
tion.3,4,8,28 To assess the degree to which AEC TP63
mutants may prevent normal induction of TP63-depen-
dent differentiation genes, we compared AEC TP63mutant
impacts on global mRNA expression during differentiation
with those of TP63 depletion (TP63i). Comparison of the
TP63i (Figures S5A and S5B and Table S5) and AEC gene
sets revealed a highly significant (p < 10148) overlap of
Figure 3. Transcriptional Profiling of AEC Model Tissue
(A) Venn diagram illustrating overlap between changes identified
in p.Ile482Thr (AEC1) and p.Arg500Pro (AEC2) AEC mutant
versus wild-type (WT) control organotypic tissue. Heat map of
the 651 genes shared between the two profiles (p value < 10250,
Fisher’s exact test); blue (repressed) and red (induced), log2-based
scale.
(B) Gene ontology (GO) analysis of the p.Ile482Thr and p.Arg500-
Pro gene-profile overlap (p values represent a Bonferroni-corrected
EASE score).
Figure 4. Identification of TP63-Dependent Candidate Regula-
tors Responsible for the AEC Phenotype
(A) Venn diagram illustrating overlap between changes identified
in AEC cultures and KCs treated with siRNA targeting total
TP63. Heat map of the 206 genes shared between the two profiles
(p value < 10148, Fisher’s exact test); blue (repressed) and red
(induced), log2-based scale.
(B) Barcode plot showing AEC and TP63i gene-number overlap
with indicated epidermal gene set.
(C) GSEA enrichment values for top overlapping gene sets.206 genes (Figure 4A and Table S6), with the repressed
genes in this narrowed set being enriched for the same
gene ontology terms identified in the p.Ile482Thr and
p.Arg500Pro AEC set (Figure 3B). AEC TP63 mutants there-
fore block induction of a number of genes that are depen-
dent on wild-type TP63 for their normal induction during
differentiation.
To gain insight into how AEC TP63 blocks differentia-
tion, we performed GSEA on the set of genes that are
both TP63-dependent during normal differentiation and
inhibited by AEC TP63 mutants, on the basis of the possi-
bility that AEC TP63 mutants might act by inhibiting the
normal TP63-dependent activation of specific differentia-
tion-enabling factors. GSEA comparison of published
gene sets for regulators of epidermal homeostasis and
differentiation identified the most significant overlap
with the epidermal differentiation regulators ZNF750,31
KLF4,32 and GRHL333 (Figures 4B and 4C; Tables S7 andThe AmericanS8), each of which was repressed by AEC mutant TP63
(Table S4). Interestingly, IRF634 (MIM 607199) and CEBPa
and CEBPb35 (MIMs 116897 and 189965) transcriptional
targets also showed significant overlap with the AEC and
TP63i gene set. Neither IRF6 nor CEBPa/b levels were
repressed by AEC mutant TP63 (Table S4), suggesting that
their full transcriptional programs may require coordina-
tion with the TP63-regulated transcriptional network.
To investigate the relationship between mutant and
wild-type TP63 and ZNF750, we performed TP63 ChIP-
Seq in proliferating versus differentiating human KCs.
This identified 6,050 total TP63-bound regions (Table S9).
Analysis of the read-signal intensities within these
regions between proliferating and differentiating KCs re-
vealed stable, unchanged TP63 binding in undifferentiated
and differentiated cells at > 94.4% of these binding
sites (Figure 5A), including two binding peaks identified
near the transcription start site (TSS) of ZNF750 (Fig-
ure 5B), both of which contain canonical TP63 binding
sequences.36 For confirmation of these results and exami-
nation of whether AEC TP63 mutants retain the capacity
to bind TP63 DNA motifs at the ZNF750 locus, TP63 ChIP
was performed on human KCs depleted of endogenousJournal of Human Genetics 91, 435–443, September 7, 2012 439
Figure 5. TP63 ChIP-Seq Identifies TP63 Binding to the ZNF750 Locus during Epidermal Differentiation
(A) Heat map showing stable p63 genomic binding in undifferentiated progenitor-containing KC populations and in differentiated KCs.
(B) TP63 binding near the TSS of the ZNF750 locus in undifferentiated progenitor-containing KC populations and in differentiated KCs.
(C) Immunoblot analysis of TP63-DNp63a in KCs infected with pBABE-Empty Vector (EV), pBABE-TP63-DNp63a-WT (WT), pBABE-
p.Ile482Thr (AEC1), and pBABE-p.Arg500Pro (AEC2) AEC TP63 mutants. Each population of KCs was treated with control or TP63 tar-
geting siRNA, as indicated.
(D) ChIP analysis comparing binding capacity of wild-type TP63 versus AEC TP63 mutants at the ZNF750 locus in undifferentiated and
differentiated KCs treated with TP63i (specific for endogenous TP63 mRNA). Error bars are5 SD between qPCR triplicate samples.TP63 by RNAi and with either wild-type TP63 or AEC TP63
mutants introduced at near-endogenous levels (Figure 5C).
In agreement with ChIP-Seq data, TP63 ChIP in control
cells showed similar TP63 binding near the ZNF750 TSS
in both progenitor and differentiated KCs. Additionally,
AEC TP63 mutants bound ZNF750 target sequences at
similar levels to wild-type TP63 (Figure 5D). ZNF750 is
thus a TP63-bound and -regulated gene whose induction
during epidermal differentiation is inhibited by AEC
TP63 mutants, which can bind the ZNF750 locus compa-
rably to wild-type TP63.
The tremendous overlap of the AEC-repressed and
ZNF750-dependent gene sets raised the possibility that
ZNF750 may be an important pathologic target of AEC
TP63 mutants that resides upstream of TP63-dependent
transcriptional targets. Consistent with this, restoring
ZNF750 expression to AEC TP63 mutant epidermal tissue
(Figure 6A) rescued expression of the majority of TP63
transcriptional targets, including GRHL3, KLF4, and
PRDM1, along with epidermal differentiation-gene expres-
sion (Figures 6B–6D). ZNF750 is therefore bound and
repressed by AEC TP63 mutants, and restoring ZNF750
expression in human AEC model tissue can rescue defects
in differentiation caused by AEC mutant TP63.
Discussion
Here, we generated a human epidermal tissue model of
AEC and then used this model to identify ZNF750 as an440 The American Journal of Human Genetics 91, 435–443, SeptembAEC TP63mutant target capable of rescuing differentiation
defects in this setting. The modeled recapitulation by
AEC mutant TP63 of the impaired differentiation seen in
AEC human skin demonstrates that repressed epidermal
differentiation seen in AEC does not solely arise from
defects occurring during epidermal-progenitor develop-
ment, but also from dysfunction within developmentally
mature cells that can be directly induced by AEC mutant
TP63. At the same time, introduction of AEC mutant
TP63 into developmentally mature KCs did not result in
diminished clonogenicity (Figure S4), as seen in a recent
mouse knockin model of AEC,29 indicating that addi-
tional AEC phenotypes arise from AEC mutant TP63
disruption of epidermal development. Differentiation-
suppressive effects of AEC mutant TP63 appeared to
require retention of mutant C-terminal TP63-DNa resi-
dues, because enforced expression of the normally non-
abundant TP63-DNd isoform, which entirely lacks the
C-terminal sequences encompassing the SAM domain,
had no such effects. Genome-wide ChIP-Seq analysis of
TP63 led to the observation that the vast majority of
wild-type TP63 DNA binding peaks are stable between
proliferating and differentiating KCs. This is consistent
with the retained levels of TP63 in both undifferentiated
basal as well as differentiating suprabasal KCs within
human epidermis.37 These data also suggest that genomic
mobilization of TP63 may not significantly contribute
to TP63 gene regulatory control of epidermal differentia-
tion. The retention of AEC mutant TP63 DNA binding ater 7, 2012
Figure 6. Rescue of AEC Differentiation
Defects by ZNF750
Human epidermal tissue was regenerated
from KCs infected with either pBABE-
Empty Vector (EV) or pBABE-p.Arg500Pro
AEC mutant TP63, then with either
pBABE-EV or pBABE-ZNF750. Quantitative
mRNA levels of (A) ZNF750 and (B)
epidermal differentiation markers and
regulators in the indicated day 4 organo-
typic tissues. Error bars are 5 SD between
triplicate samples. Differentiation proteins
KRT1 (C) and FLG (D) in the indicated or-
ganotypic tissues.canonical TP63 DNA binding sites located near the
ZNF750 TSS suggests that dominant-negative AEC TP63
mutant impacts on differentiation do not require disrup-
tion of TP63 DNA binding capacity.
Prior work studying AEC skin9,38 demonstrated normal
suprabasal KRT10 levels in several AEC individuals, in
contrast to other published work,28 which showed dimin-
ished-to-absent KRT1 in lesional AEC tissue, which is in
agreement with the present study. Several factors may
account for this discrepancy. First is the issue of lesional
versus nonlesional AEC skin. The skin lesions in AEC
generally do not affect the majority of the skin surface
and have been observed to affect neonates most severely
and then improve over time, indicating that AEC mutant
TP63-associated skin defects undergo eventual compensa-
tion. The findings of Koster et al.28 are consistent with
this, in that impaired differentiation was only observed
in the lesional, but not the nonlesional, AEC skin of the
same individual. In spite of this, however, it is important
to note that the study by McGrath et al.9 did carefully
demonstrate abnormal distribution of another differentia-
tion marker, namely FLG, providing further support for
abnormal epidermal differentiation in AEC. Moreover,
the work by Browne et al.38 demonstrated that AEC
mutant TP63 failed to normally transactivate epidermal
differentiation promoters, further consistent with an
adverse differentiation impact of AEC mutant TP63. In
the present study, lesional skin from an AEC-affected
newborn recapitulated Koster et al.’s28 findings of impaired
KRT1 levels, as well as also showing diminished FLG. It is
also possible that the differences in these bodies of work
could be due to characteristics of individual AEC muta-
tions. Differentiation-protein levels were studied in only
three individuals total in the two papers by McGrathThe American Journal of Human Genet al.9 and Browne et al.38 noted
above, with alterations p.Gly534Trp,
p.Thr533Pro, and p.Gly561Asp,
which were not analyzed in the
current work. Thus, this possibility
cannot be excluded; however, the
noted strikingly different differentia-
tion picture seen between lesional
and nonlesional skin in the sameAEC individual by Koster et al.28 and the FLG abnormali-
ties observed even in what appears to have been non-
lesional skin byMcGrath et al.9 support a primary differen-
tiation impact that undergoes compensation over time,
consistent with the well-observed clinical skin improve-
ments in individuals with AEC postinfancy.
The finding that restored expression of ZNF750 rescued
defective differentiation-gene expression in AEC model
tissue supports a model in which AEC mutants block
proximal differentiation mediators required for the activa-
tion of the epidermal differentiation program. In this
regard, transcriptional profiling of model AEC tissue led
to the identification of a set of repressed transcriptional
activators of epidermal differentiation regulators, which
included HOPX, GRHL3, KLF4, PRDM1, and ZNF750.
These regulators were confirmed to be both normally
TP63-dependent and also suppressed by AEC TP63
mutants (Table S6). Remarkably, GSEA revealed that the
recently characterized ZNF750-KLF4 differentiation axis31
accounted for a major portion of the epidermal differenti-
ation repressed by AEC mutant TP63. In AEC model
tissue, expression of ZNF750 rescued both the expression
of these transcription factors as well as epidermal differen-
tiation-gene expression. This suggests that ZNF750
repression by AEC TP63 mutants may be a proximal event
in the pathogenesis of disrupted differentiation in AEC
and supports the rationale for potential genetic and
other therapeutic efforts to upregulate epidermal ZNF750
in AEC.Supplemental Data
Supplemental data include five figures and nine tables and can be
found with this article online at http://www.cell.com/AJHG/.etics 91, 435–443, September 7, 2012 441
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